Showing 1672 results
-
Press release /Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of…
-
Press release /Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between…
-
Press release /The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in…
-
Press release /The three-year relapse-free survival (RFS) rate for patients treated with the combination was 58%, compared to 39% with placebo[1] Consistent improvement in RFS observed across all pre-specified…
-
Story /Novel digital platform for clinical trial data collection could help facilitate much-needed biomedical research in lower-income countries.
-
Story /Our Global Head of Talent Acquisition & Staffing talks about ongoing recruitment efforts to create a more diverse and inclusive organization.
-
Story / -
Story /Groups of people doing communal exercises are an everyday sight in Japan, but for one woman they are a very public way to show she is fighting back.
-
Story /Two Novartis leaders share their perspectives on digital health in 2020 – and the key trends to watch out for over the next 12 months.